Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 5/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | XBP1 | P17861 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | TNKS | O95271 | 1/20 | 0.58 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 2/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125184 | 0.87 | ELANE (0.93) | ELANENPC1RAB9ARXFP1ALDH1A1 | |
| SCHEMBL29456973 | 0.87 | ELANE (0.93) | ELANENPC1RAB9ARXFP1ALDH1A1 | |
| SCHEMBL12212888 | 0.86 | ELANE (0.89) | ELANENPC1RAB9ARXFP1ALDH1A1 | |
| SCHEMBL3254378 | 0.86 | ELANE (0.89) | ELANENPC1RAB9ARXFP1ALDH1A1 | |
| SCHEMBL11817024 | 0.85 | ELANE (0.71) | ELANENPC1RAB9ARXFP1ALDH1A1 | |
| SCHEMBL273036 | 0.84 | ELANE (0.93) | ELANENPC1RAB9ARXFP1ALDH1A1 | |
| SCHEMBL29382161 | 0.84 | ELANE (1.00) | ELANENPC1RAB9ARXFP1ALDH1A1 | |
| SCHEMBL272702 | 0.84 | ELANE (1.00) | ELANENPC1RAB9ARXFP1ALDH1A1 | |
| SCHEMBL914482 | 0.83 | NPC1 (1.00) | ELANENPC1RAB9ARXFP1ALDH1A1 | |
| SCHEMBL6770574 | 0.82 | F2 (0.49) | ELANENPC1RAB9ARXFP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| US-7129245-B2 | Anticoagulants which act selectively on factor Xa; fast acting; oral; do not interfere with lysis of blood clots | ELI LILLY AND COMPANY (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| US-20050282862-A1 | Aromatic amides | BEIGHT DOUGLAS W | 2005-12-22 | — | — | US | disclosed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| EP-1140903-B1 | AROMATIC AMIDES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6759414-B2 | ANTICOAGULANTS WHICH ACT SELECTIVELY ON FACTOR XA; FAST ACTING; ORAL; DO NOT INTERFERE WITH LYSIS OF BLOOD CLOTS | ELI LILLY AND COMPANY | 2004-07-06 | — | — | US | disclosed |
| US-20040029874-A1 | Aromatic amides | BEIGHT DOUGLAS WADE (US) | 2004-02-12 | — | — | US | disclosed |
| US-6635657-B1 | Pyridine derivatives; anticoagulants | ELI LILLY AND COMPANY | 2003-10-21 | — | — | US | disclosed |
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029874-A1 | Aromatic amides | F11, F12, F5 | ELANE 741/4885NPC1 1659/4885RAB9A 2097/4885 |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | ELANE 353/4885NPC1 4151/4885RAB9A 3514/4885 |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | ELANE 130/4885NPC1 1618/4885RAB9A 2658/4885 |
| US-20050282862-A1 | Aromatic amides | F11, F12, F5 | ELANE 741/4885NPC1 1659/4885RAB9A 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.